Fvefrenz Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 1.00 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2019
- Revenue Growth 30.23%
- Profit Growth -1658.27%
- Ebitda -570.06%
- Net Worth -113.22%
- Total Assets -25.50%
About Fvefrenz Pharmaceutical
Fvefrenz Pharmaceutical Private Limited (FPPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 March 2016 (Eight years and 11 months 7 days old ). Its registered office is in Udaipur, Rajasthan, India.
The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Subhash George and Vijay Sengar serve as directors at the Company.
Company Details
-
Location
Udaipur, Rajasthan, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232RJ2016PTC049568
-
Company No.
049568
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Mar 2016
-
Date of AGM
30 Sep 2019
-
Date of Balance Sheet
31 Mar 2019
-
Listing Status
Unlisted
-
ROC Code
Roc Jaipur
Industry
Who are the key members and board of directors at Fvefrenz Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Subhash George
|
Director | 11-Mar-2016 | Current |
|
Vijay Sengar
|
Director | 13-May-2019 | Current |
Financial Performance of Fvefrenz Pharmaceutical.
Fvefrenz Pharmaceutical Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 30.23% increase. The company also saw a substantial fall in profitability, with a 1658.27% decrease in profit. The company's net worth observed a substantial decline by a decrease of 113.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Fvefrenz Pharmaceutical?
In 2018, Fvefrenz Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Horeb Lifesciences (Opc) Private LimitedSubhash George is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Fvefrenz Pharmaceutical?
Unlock and access historical data on people associated with Fvefrenz Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Fvefrenz Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Fvefrenz Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
